Arsanis, Inc. | Business Contracts

Amendment No. 2 to Amended and Restated Loan and Security Agreement, dated as of December 21, 2020, by and among X4 Pharmaceuticals, Inc., each of its Qualified Subsidiaries... (Filed With SEC on December 23, 2020)

Lease Termination Agreement, dated July 17, 2020, by and between 955 Massachusetts Avenue MA, LLC and X4 Pharmaceuticals, Inc (Filed With SEC on November 5, 2020)

Consulting agreement, dated September 17 2020, by and between X4 Pharmaceuticals Inc. and Gary Bridger (Filed With SEC on November 5, 2020)

Description of Registered Securities (Filed With SEC on March 12, 2020)

Master Services Agreement, dated September 10, 2015, by and between X4 Pharmaceuticals Inc. and Mayne Pharma Inc. (formerly known as Metrics, Inc.) (Filed With SEC on March 12, 2020)

Exclusive License Agreement, dated as of December 23, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Beth Israel Deaconess Medical Center (Filed With SEC on May 13, 2019)

Second Amendment to Agreement and Plan of Merger, dated March 8, 2019, by and among Arsanis, Inc., Artemis AC Corp. and X4 Pharmaceuticals, Inc (Filed With SEC on March 8, 2019)

Common Stock Purchase Agreement, dated October 14, 2020, by and between X4 Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (Filed With SEC on October 16, 2020)

Registration Rights Agreement, dated October 14, 2020, by and between X4 Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (Filed With SEC on October 16, 2020)

Amendment to Amended and Restated Executive Employment Agreement, dated as of March 13, 2019, dated February 13, 2020 by and between the Company and Paula Ragan, Ph.D (Filed With SEC on May 7, 2020)

Resignation Agreement and Release by and between X4 Pharmaceuticals, Inc. and E. Lynne Kelley, M.D., dated March 18, 2020 (Filed With SEC on March 20, 2020)

Amendment No. 1 to Loan and Security Agreement, dated March 13, 2020, by and between X4 Pharmaceuticals, Inc. and Hercules Capital, Inc (Filed With SEC on March 17, 2020)

Executive Employment Agreement, dated as of April 16, 2019, by and between the Company and E. Lynne Kelley (Filed With SEC on March 12, 2020)

Amendment to Amended and Restated Executive Employment Agreement, dated as of March 13, 2019, dated February 13, 2020 by and between the Company and Paula Ragan, Ph.D (Filed With SEC on March 12, 2020)

Amendment to Amended and Restated Executive Employment Agreement, dated as of February 24, 2020 by and between the Company and Adam S. Mostafa (Filed With SEC on March 12, 2020)

Amendment to Executive Employment Agreement, dated as of March 5, 2020, by and between the Company and E. Lynne Kelley (Filed With SEC on March 12, 2020)

Executive Employment Agreement, dated as of September 25, 2019, by and between the Company and Derek Meisner (Filed With SEC on March 12, 2020)

Amendment to Executive Employment Agreement, dated as of February 24, 2020, by and between the Company and Derek Meisner (Filed With SEC on March 12, 2020)

Amendment No. 1 to Master Services Agreement, dated August 25, 2017, by and between X4 Pharmaceuticals Inc. and Mayne Pharma Inc. (formerly known as Metrics, Inc.) (Filed With SEC on March 12, 2020)

Amendment No. 2 to Master Services Agreement, dated February 28, 2020, by and between X4 Pharmaceuticals Inc. and Mayne Pharma Inc (Filed With SEC on March 12, 2020)

Master Services Agreement, dated February 19, 2016, by and between X4 Pharmaceuticals Inc. and Aptuit (Oxford) Limited (Filed With SEC on March 12, 2020)

Amendment No. 1 to Master Services Agreement, dated February 19, 2016, by and between X4 Pharmaceuticals Inc. and Aptuit (Oxford) Limited (Filed With SEC on March 12, 2020)

Lease, dated as of November 11, 2019, by and between X4 Pharmaceuticals Inc. and Beacon North Village, LLC (Filed With SEC on March 12, 2020)

Underwriting Agreement, dated November 26, 2019, by and among the Company, Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on November 27, 2019)

Form of Pre-Funded Warrant (Filed With SEC on November 27, 2019)

Form of Class B Warrant (Filed With SEC on November 27, 2019)

Amended and Restated Loan and Security Agreement, dated as of June 27, 2019, by and among X4 Pharmaceuticals, Inc., X4 Therapeutics, Inc., Hercules Capital, Inc. and Hercules... (Filed With SEC on June 28, 2019)

Form of Restricted Stock Unit Agreement under the Companys 2017 Equity Incentive Plan (Filed With SEC on June 19, 2019)

Form of Restricted Stock Unit Agreement under the 2019 Inducement Equity Incentive Plan (Filed With SEC on June 19, 2019)

Form of Restricted Stock Agreement under the 2019 Inducement Equity Incentive Plan (Filed With SEC on June 19, 2019)

Form of Stock Option Agreement under the 2019 Inducement Equity Incentive Plan (Filed With SEC on June 19, 2019)

X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (Filed With SEC on June 19, 2019)

Form of Restricted Stock Unit Agreement under the Companys 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (Filed With SEC on June 19, 2019)

Form of Incentive Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on May 15, 2019)

Form of Nonstatutory Stock Option Agreement under the 2017 Equity Incentive Plan (Filed With SEC on May 15, 2019)

Form of Nonstatutory Stock Option Agreement (Director Grants) under the 2017 Equity Incentive Plan (Filed With SEC on May 15, 2019)

Form of Restricted Stock Agreement under the 2017 Equity Incentive Plan (Filed With SEC on May 15, 2019)

Warrant Agreement, dated as of March 18, 2019, by and between the Company and Hercules Capital, Inc (Filed With SEC on May 15, 2019)

Amended and Restated Warrant Agreement, dated as of March 29, 2019, by and between the Company and Hercules Capital, Inc (Filed With SEC on May 15, 2019)

License Agreement, dated as of December 13, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Georgetown University (Filed With SEC on May 13, 2019)

Amendment No. 1 to License Agreement, dated as of October 23, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Genzyme Corporation, a Sanofi... (Filed With SEC on May 13, 2019)

License Agreement, dated as of July 10, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, LLC) and Genzyme Corp., a Sanofi company (Filed With SEC on May 13, 2019)

Form of Pre-Funded Warrant (Filed With SEC on April 15, 2019)

Form of Class A Warrant (Filed With SEC on April 15, 2019)

Underwriting Agreement, dated April 12, 2019, by and among the Company, Cowen and Company, LLC and Stifel, Nicolaus & Company, Incorporated (Filed With SEC on April 15, 2019)

Settlement Agreement, dated as of March 8, 2019, by and among X4 Pharmaceuticals, Inc. (formerly Arsanis, Inc.), Artemis AC Corp., X4 Therapeutics, Inc. (formerly X4... (Filed With SEC on April 11, 2019)

Form of Stock Option Agreement under the 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (Filed With SEC on April 3, 2019)

Director Compensation Policy (Filed With SEC on March 13, 2019)

Form of Common Stock Certificate (Filed With SEC on March 13, 2019)

Form of Warrant to Purchase Series A Preferred Stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) issued to Silicon Valley Bank and Life Science Loans, LLC (Filed With SEC on March 13, 2019)

Form of Warrant to Purchase Series A Preferred Stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) issued to Maxim Partners LLC (Filed With SEC on March 13, 2019)

Form of Warrant to Purchase Series B Preferred Stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) (Filed With SEC on March 13, 2019)

Form of Warrant to Purchase Series B Preferred Stock of X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) issued to Hercules Capital, Inc (Filed With SEC on March 13, 2019)

Warrant Modification Agreement, dated as of December 11, 2018, by and among X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Hercules Capital, Inc (Filed With SEC on March 13, 2019)

2015 Employee, Director and Consultant Equity Incentive Plan, as amended (Filed With SEC on March 13, 2019)

Form of Stock Option Agreement under the 2015 Employee, Director and Consultant Equity Incentive Plan, as amended (Filed With SEC on March 13, 2019)

Amended and Restated Executive Employment Agreement, dated as of March 13, 2019, by and between the Company and Adam S. Mostafa (Filed With SEC on March 13, 2019)

Amended and Restated Executive Employment Agreement, dated as of March 13, 2019, by and between the Company and Paula Ragan, Ph.D (Filed With SEC on March 13, 2019)

License Agreement, dated as of July 10, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, LLC) and Genzyme Corp., a Sanofi company (Filed With SEC on March 13, 2019)

Amendment No. 1 to License Agreement, dated as of October 23, 2014, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Genzyme Corporation, a Sanofi... (Filed With SEC on March 13, 2019)

License Agreement, dated as of December 13, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Georgetown University (Filed With SEC on March 13, 2019)

Exclusive License Agreement, dated as of December 23, 2016, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Beth Israel Deaconess Medical Center (Filed With SEC on March 13, 2019)

Loan and Security Agreement, dated as of October 19, 2018, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Hercules Capital, Inc (Filed With SEC on March 13, 2019)

Amendment No. 1 to Loan and Security Agreement, dated as of December 11, 2018, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Hercules Capital, Inc (Filed With SEC on March 13, 2019)

Lease, dated as of January 20, 2017, by and between X4 Therapeutics, Inc. (formerly X4 Pharmaceuticals, Inc.) and Brickman 955 Massachusetts LLC (Filed With SEC on March 13, 2019)

Lease Termination Agreement, dated February 26, 2019, by and between Arsanis Biosciences GmbH and Wstenrot Marxbox GmbH & Co. OG (as successor-in-interest to Marxbox Bauprojekt... (Filed With SEC on March 1, 2019)

Arsanis, Inc. (66)